Trump administration political appointees and Congressional Democrats may be headed for a significant battle over the 2027 user fee reauthorization package, comments made Friday during the Food and Drug Law Institute annual conference in Washington, DC, suggest.
Key Takeaways
- The 2027 FDA user fee reauthorization process may be shaped by political disagreements.
Many of the US Food and Drug Administration’s current user fee packages will expire in late 2027 and must be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?